Generic Drugs
•10 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (10)
| Company | Market Cap | Price |
|---|---|---|
|
ABT
Abbott Laboratories
Abbott competes in generic drug segments across emerging markets, aligning with the Generic Drugs theme within Established Pharmaceutical Products.
|
$215.16B |
$123.64
-0.83%
|
|
CAH
Cardinal Health, Inc.
CAH operates a generics program contributing to revenue and margins.
|
$45.55B |
$190.72
+0.46%
|
|
VTRS
Viatris Inc.
Viatris is a large-scale producer of generic medicines and biosimilars, core to its business.
|
$12.16B |
$10.36
|
|
RDY
Dr. Reddy's Laboratories Limited
Core business focused on manufacturing and selling generic drugs.
|
$11.09B |
$13.30
-1.12%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Main revenue driver is generic drugs in Affordable Medicines.
|
$3.39B |
$10.82
+8.20%
|
|
ANIP
ANI Pharmaceuticals, Inc.
Generics business forms a major revenue stream, with numerous generic products and the Prucalopride CGT-exclusive launch.
|
$1.96B |
$90.62
-1.42%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Core legacy business includes generic drug development/manufacturing with observed generic competition dynamics.
|
$1.20B |
$25.52
+3.49%
|
|
ELTP
Elite Pharmaceuticals, Inc.
Elite focuses on the development, manufacture, and sale of generic drugs across a broad pipeline.
|
$18.04M |
$0.61
|
|
SBFM
Sunshine Biopharma, Inc.
SBFM's Nora Pharma operates a growing Canadian generic prescription drug business.
|
$8.06M |
$1.78
+2.00%
|
|
CPHI
China Pharma Holdings, Inc.
Core product: generic drugs manufacturing (Helpson's portfolio in PRC).
|
$5.35M |
$1.65
-4.62%
|
Loading company comparison...
Loading industry trends...
Loading research report...
